tiprankstipranks
PolyPid Advances Trial for Infection Prevention
Company Announcements

PolyPid Advances Trial for Infection Prevention

PolyPid (PYPD) has released an update.

Don't Miss our Black Friday Offers:

PolyPid Ltd. has discussed the rising challenge of surgical site infections (SSIs) and highlighted its ongoing SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing SSIs in abdominal surgeries. The trial has currently enrolled about 250 of the planned 600 patients, with interim analysis expected after 400 patients complete a 30-day follow-up, and top-line results anticipated in early 2025. The company’s D-PLEX100 product, which releases antibiotics over 30 days, could improve patient outcomes and reduce healthcare costs associated with SSIs.

For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskPolyPid Reports Q3 Results Amid SHIELD II Trial Progress
TipRanks Auto-Generated NewsdeskPolyPid Announces SHIELD II Trial Progress and Financials
TheFlyPolyPid reports Q3 EPS ($1.22), consensus ($1.00)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App